Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

Introduction to a review series on rare systemic hematologic disorders

Nancy Berliner, Laurie Sehn

Blood (2020) 135 (16): 1305.

https://doi.org/10.1182/blood.2019004082

Published: 2020

Journal Articles

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

Ciara L. Freeman, Franck Morschhauser, Laurie Sehn, Mark Dixon, Richard Houghton, Thierry Lamy, Günter Fingerle-Rowson, Elisabeth Wassner-Fritsch, John G. Gribben, Michael Hallek, Gilles Salles, Guillaume Cartron

Blood (2015) 126 (24): 2646–2649.

https://doi.org/10.1182/blood-2015-09-670802

Published: 2015

Journal Articles

An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup

Blood (2015) 125 (6): 959–966.

https://doi.org/10.1182/blood-2013-06-507152

Published: 2015

Includes: Supplemental data

Journal Articles

Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP

Blood (2010) 116 (21): 2005.

https://doi.org/10.1182/blood.V116.21.2005.2005

Published: 2010

Journal Articles

Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma

Rashmi S. Goswami, BSc, MD, FRCPC, Levi Waldron, Ph.D., Patricia P Reis, Ph.D., Yali Xuan, Wei Xu, Ph.D., John Kuruvilla, David Good, MD, Denis Bailey, MD, Alanna Church, MD, Tara Baetz, MD, David LeBrun, MD, Raymond Lai, MD, Ph.D., Laurie Sehn, MD, MPH, Pedro Farinha, MD, Randy D. Gascoyne, MD, Michael Crump, MD, FRCPC, Igor Jurisica, Ph.D., Suzanne Kamel-Reid, Ph.D.

Blood (2010) 116 (21): 800.

https://doi.org/10.1182/blood.V116.21.800.800

Published: 2010

Journal Articles

Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials

Joseph M. Connors, MD, Randy D. Gascoyne, MD, Paul Hoskins, MD, James Morris, MD, Tom Pickles, MD, FRCPC, Laurie Sehn, MD, MPH, Tamara Shenkier, MD, Richard Klasa, MD, CM, FRCP(C), Nicholas Voss, MD, Kerry Joanne Savage, MD, BSc, MSc

Blood (2010) 116 (21): 417.

https://doi.org/10.1182/blood.V116.21.417.417

Published: 2010

Journal Articles

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

Alden A. Moccia, Felicitas Hitz, Paul Hoskins, Richard Klasa, Maryse Power, Kerry J. Savage, Tamara Shenkier, John Shepherd, Brian Skinnider, Graham W. Slack, Kevin Song, Randy D. Gascoyne, Joseph M. Connors, Laurie Sehn

Blood (2010) 116 (21): 113.

https://doi.org/10.1182/blood.V116.21.113.113

Published: 2010

Journal Articles

ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.

Rita Shaknovich, MD/PhD, Huimin Geng, Ph.D., Nathalie Johnson, MD, Leandro Cerchietti, MD, Maria E Figueroa, MD, Lucas Tsikitas, Olivier Elemento, Ph.D., Joseph M. Connors, MD, Laurie Sehn, MD, MPH, Randy D. Gascoyne, MD, Ari Melnick, MD

Blood (2009) 114 (22): 619.

https://doi.org/10.1182/blood.V114.22.619.619

Published: 2009

Journal Articles

Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP

Jesse Shustik, MD, Christian Steidl, MD, Laurie Sehn, MD, MPH, Randy D Gascoyne, MD

Blood (2008) 112 (11): 3782.

https://doi.org/10.1182/blood.V112.11.3782.3782

Published: 2008

Journal Articles

Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.

David Hui, MD, MSc, Jane Donaldson, Paul Hoskins, MD, Richard Klasa, MD, Kerry J. Savage, MD, MPH, Tamara Shenkier, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD, Laurie Sehn, MD, MPH

Blood (2007) 110 (11): 1563.

https://doi.org/10.1182/blood.V110.11.1563.1563

Published: 2007

Journal Articles

CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma.

Nathalie A. Johnson, Steven Leach, Laurie Sehn, Joseph M. Connors, Angela Brooks-Wilson, Randy D. Gascoyne

Blood (2007) 110 (11): 686.

https://doi.org/10.1182/blood.V110.11.686.686

Published: 2007

Journal Articles

Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.

Pedro Farinha, MD, Laurie Sehn, MD, Brian Skinnider, MD, Lin Wu, Nancy Patten, Sim Truong, Joseph M. Connors, MD, Randy D. Gascoyne, MD

Blood (2006) 108 (11): 812.

https://doi.org/10.1182/blood.V108.11.812.812

Published: 2006

Journal Articles

Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL).

Pedro Farinha, MD, Laurie Sehn, MD, Brian Skinnider, MD, Joseph M. Connors, MD, Randy D. Gascoyne, MD

Blood (2006) 108 (11): 816.

https://doi.org/10.1182/blood.V108.11.816.816

Published: 2006

Journal Articles

Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R).

N.A. Johnson, MD, T. Relander, MD, P. Farinha, MD, T. Nayar, D.E. Horsman, MD, Joseph M. Connors, MD, Laurie Sehn, MD, Randy D. Gascoyne, MD

Blood (2006) 108 (11): 2027.

https://doi.org/10.1182/blood.V108.11.2027.2027

Published: 2006

Journal Articles

Phase II Trial of Bortezomib in Mantle Cell Lymphoma.

Andrew Belch, FRCPC, C. Tom Kouroukis, Michael Crump, Laurie Sehn, Randy Gascoyne, Richard Klasa, Powers Jean, Elizabeth Eisenhauer

Blood (2004) 104 (11): 608.

https://doi.org/10.1182/blood.V104.11.608.608

Published: 2004

NARROW

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Introduction to a review series on rare systemic hematologic disorders

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup

Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP

Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma

Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.

Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP

Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.

CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma.

Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.

Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL).

Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R).

Phase II Trial of Bortezomib in Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only